Everything tagged "biotechnology" across research, earnings, and macro.
21 articles
Alnylam just got the kind of competitive win biotech investors rarely get handed this cleanly: a rival late-stage ATTR-CM miss after AMVUTTRA already secured the label and commercial traction. With revenue up 65.2% year over year and AMVUTTRA driving more than $1 billion in quarterly product revenue, the stock still looks like the clearest winner in a narrowing field.
Ionis got hit as if the Wainua trial miss broke the whole equity story, and that looks too simplistic. The bigger near-term driver is now TRYNGOLZA's expanded launch, with commercial revenue already up 42% and management raising its olezarsen peak-sales view above $3 billion.
Ionis is evolving into a multi-product commercial RNA medicines company, with TRYNGOLZA and DAWNZERA driving real revenue growth and a larger market opportunity now open for TRYNGOLZA.
BridgeBio has evolved from a pipeline biotech into a commercial-stage rare-disease story, led by explosive Attruby sales and a late-stage pipeline. The stock still carries meaningful balance-sheet risk, but the launch momentum is real.
Alnylam has evolved into a commercial RNAi leader, with AMVUTTRA powering rapid revenue growth and a strong balance sheet supporting the next leg. The stock earns a Buy as the TTR franchise scales and profitability improves.
Summit Therapeutics is a high-risk, high-upside oncology story built around ivonescimab, with positive Phase III data and an FDA review underway. The stock looks attractive for investors willing to accept binary regulatory risk in exchange for platform-scale potential.
Nuvectis took a painful dilution hit, but this is one of the rare biotech raises that actually improves the story. A $100 million financing landed right after a pipeline expansion deal, turning NVCT from a cash-tight single-asset bet into a funded three-program clinical setup.
Vertex’s CASGEVY expansion to patients as young as 2 looks like a real commercial runway extension, not a cosmetic label update. With elite margins, strong growth, and a TickerSpark Score of 89, the stock still looks built for more than a one-day pop.
Summit Therapeutics is trading like the financing scare already came and went. The rebound says the market cares more about ivonescimab's November 14, 2026 FDA clock and funded Phase III runway than a headline offering that never even closed.
Vertex combines a dominant cystic fibrosis franchise with early diversification in rare disease and acute pain. The stock looks like a disciplined Buy, but valuation still depends on execution across ALYFTREK, CASGEVY, JOURNAVX, and the renal pipeline.
Moderna is a transition story with real mRNA platform strength, but weak earnings and heavy COVID dependence keep it in Hold territory. The stock’s appeal hinges on late-stage pipeline catalysts and a cash runway that supports the pivot.
Incyte is still being traded like Jakafi is the whole story, and that framing is getting stale. Revenue grew 21% in Q1, Jakafi XR is already approved, and a September FDA catalyst gives the pipeline a much more investable shape than the stock seems to reflect.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator